Presence of genetic aberrations in patients with brain metastases from non-small cell lung cancer (NSCLC) and clinical outcomes.
Robert H. Press(Baptist Hospital of Miami), Kristin Higgins(Emory University), Richard J. Cassidy(Florida Cancer Specialists & Research Institute), Gabriel Sica(Emory University), Pretesh Patel(Emory University), Walter J. Curran(Piedmont Cancer Institute), Matthew J. Ferris(University of Maryland, Baltimore), Taofeek K. Owonikoko(UPMC Hillman Cancer Center), Conor Steuer(Emory University), Suresh S. Ramalingam(Emory University), Xinyan Zhang(Jinzhou Central Hospital), Jim Zhong(Emory University), Hui-Kuo George Shu(Emory University), Rathi N. Pillai(Emory University)
Cited by 1
Related Papers
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
|The Lancet|2004|2.4k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
|Journal of Clinical Oncology|2013|1.1k